Growth hormone secretagogue receptor antagonists

Area of Science:

• Pharmacology
• Endocrinology
• Medicinal Chemistry

Background:

• The ghrelin receptor, also known as the growth hormone secretagogue receptor (GHSR) 1A, plays a crucial role in regulating appetite and energy balance.
• Ghrelin receptor agonists stimulate food intake and promote weight gain, making antagonists potential therapeutic targets for obesity and metabolic disorders.

Purpose of the Study:

• To identify and characterize novel peptidic and nonpeptidic inhibitors of the ghrelin receptor (GHSR 1A).
• To investigate the potential of modified ghrelin peptide agonists as antagonists for therapeutic applications in metabolic diseases.

Main Methods:

• Patent analysis of peptidic/nonpeptidic GHSR 1A inhibitors.
• Chemical modification of ghrelin peptide agonists by adding a GlyMetAla tripeptide at the N-terminus.
• In vivo studies in rat models to assess the efficacy of developed compounds.

Main Results:

• The addition of a GlyMetAla tripeptide to ghrelin peptide agonists successfully converted them into ghrelin receptor antagonists.
• One such modified peptide demonstrated significant reduction in food intake in rats.
• This peptide also exhibited a notable decrease in body weight gain in the studied rat models.

Conclusions:

• Novel ghrelin receptor antagonists can be developed by modifying existing peptide agonists.
• These antagonists hold promise as potential therapeutic agents for managing obesity and related metabolic conditions.
• Further in vivo validation supports the anti-obesity effects of these ghrelin receptor antagonists.